| 921/1507 | US=58 / Câncer Hurley PJ, Bunz F. Distinct pathways involved in s-phase checkpoint control. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 27-36. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CONTROLO S-CHECKPOINT; INTRA-S-FASE CHECKPOIN; CHECKPOIN REPLICACAO; S-M CHECKPOINT; ATR; CHK1; CHK2; REPLICACAO DO DNA |
| 922/1507 | US=58 / Câncer Kuang J, Wang R. Mechanisms of G2 phase arrest in DNA damage-induced checkpoint response. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 37-51. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. G2 CHECKPOINT; CDC25; PP2A; 14-3-3; 14-3-3O; P53; P21; GADD45 |
| 923/1507 | US=58 / Câncer Krämer A. Centrosomes in checkpoint responses. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 53-67. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CENTROSSOMAS NAS RESPOSTAS CHECKPOINT; CENTROSSOMA; DANOS NO DNA; CHECK-POINT; CHK1; PERICENTRIN; MICROCEFALINA; CDC25; SINDROME SECKEL; MICROCEFALIA; AMPLIFICACAO CENTROSSOMA; CATASTROFE MITOTICA |
| 924/1507 | US=58 / Câncer Lee MH, Yeung SCJ, Yang HY. Interplay of 14-3-3 family of proteins with DNA damage-regulated molecules in checkpoint control. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 69-80. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. FAMILIA DE PROTEINAS COM 14-3-3; DANOS AO DNA; RESPOSTA CHECKPOINT; 14-3-3; AKT; MDM2; P53; DANOS NO DNA |
| 925/1507 | US=58 / Câncer Nakanishi M. Chromatin modifications and orchestration of checkpoint response in cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 83-93. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. MODIFICACOES DE CROMATINA; ORQUESTRACAO DE RESPOSTA; CONTROLE EM CANCER; CHK1; CHK2; P53; REPLICACAO DO DNA |
| 926/1507 | US=58 / Câncer Kaina B, Roos WP, Christmann M. DNA damage response and the balance between cell survival and cell death. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 95-108. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DANOS NO DNA; SOBREVIVENCIA CELULAR; MORTE CELULAR; CHECKPOINTS; CICLO CELULAR; RESPOSTA A DANOS DO DNA; REPARACAO DO ADN; P53; APOPTOSE; RECEPTORES DE MORTE; FAS; CAIXA ELETRONICO; ATR; DROGAS ANTICANCER |
| 927/1507 | US=58 / Câncer Pentimalli F, Cito L, Giordano A. Dysfunction of the RB retinoblastoma gene in cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 109-22. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DISFUNCAO DO GENE; RETINOBLASTOMA RB NO CANCER; RETINOBLASTOMA; FAMILIA RB; SUPRESSORES TUMORAIS; CICLO CELULAR; G1-S DE TRANSICAO; CHECKPOINTS; E2F |
| 928/1507 | US=58 / Câncer Alao JP. G1 phase cyclins in cancer development and progression. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 123-53. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. FASE G1; CICLINAS EM CANCER; CICLO CELULAR; FASE G1; CICLINA D1; CICLINA E; CANCER; ONCOGENE; UBIQUITINA; PROTEASSOMA 26S; TERAPIA DO CANCER |
| 929/1507 | US=58 / Câncer Friedenson B. The BRCA1/2 pathway prevents some leukemias and lymphomas in addition to breast/ovarian cancers: malignancies that overcome checkpoint controls. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 155-68. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. BRCA1; BRCA2; REPARACAO DO ADN; LEUCEMIAS; LINFOMAS; LINFOMA DE CELULAS DO MANTO; LEUCEMIA MIELOIDE AGUDA |
| 930/1507 | US=58 / Câncer Post SM, Quinás-Cardama A, Lozano G. Regulation of p53 activity and associated checkpoint controls. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 171-88. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. P53; MDM2; P19; TUMORIGENESE; CANCER; RAS; CICLO CELULAR; RB; CICLINA; CDK |
| 931/1507 | US=58 / Câncer Eastman A. The importance of p53 signaling in the response of cells to checkpoint inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 189-98. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DANOS NO DNA; PARADA DO CICLO CELULAR; P53; P21; CICLINA B; CHK1 INIBIDORES; UCN-01; INIBIDORES DA TOPOISOMERASE II; ANALOGOS DE NUCLEOSIDOS |
| 932/1507 | US=58 / Câncer Siddik ZH. Targeting p21-dependent pathways for cell death in cancer therapy. In: ___. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 199-213. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DANOS NO DNA; P21; CICLINA DEPENDENTE DE QUINASE; G1 RESPOSTA CHECKPOINT; PARADA DO CICLO CELULAR; TRANSATIVACAO; PARADA DO CICLO GENE |
| 933/1507 | US=58 / Câncer Le XF, Bast Junior RC. p27Kip1 as a biomark and target for treatment of cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 215-33. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. P27KIP1; CICLO CELULAR; SUPRESSOR DE TUMOR; TERAPIA ALVO; TRASTUZUMAB |
| 934/1507 | US=58 / Câncer Pevarello P, Bischoff JR, Mercurio C. Targeting cyclin-dependent kinases with small molecular inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 235-44. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CICLINA DEPENDENTE DE QUINASE; INIBIDOR DE MOLECULA PEQUENA; SELETIVIDADE; DE MULTI-ALVO; ENSAIOS CLINICOS |
| 935/1507 | US=58 / Câncer Zhang H, Xiao Z, Sowin T. ChK1 and ChK2 as checkpoint targets. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 245-59. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CHK1; CHK2; INIBIDORES; PARADA DO CICLO CELULAR; REVOGACAO DA RESPOSTA CHECKPOINT; CHEMOPROTECTION; BIOMARCADORES PREDITIVOS |
| 936/1507 | US=58 / Câncer Rudolph J. Targeting Cdc25 phosphatases in cancer therapy. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 261-9. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CDC25 FOSFATASE; CICLO CELULAR; CANCER; AGENTES ANTI-PROLIFERATIVOS |
| 937/1507 | US=7 / Farmacologia Wells BG, DiPiro JT, Schwinghammer TL, DiPiro Cecily V. Hormone therapy in women. In: ___. Pharmacotherapy handbook. 7th ed. New York: McGraw-Hill, 2008. p. 341-52. ISBN 978-0-07-148501-2. TERAPIA HORMONAL EM MULHERES; MENOPAUSA; REGIMES HORMONAIS; ESTROGENOS; PROGESTINAS; ANDROGENOS; TIBOLONA; TERAPIA DE REPOSICAO HORMONAL; RISCO DE TERAPIA HORMONAL |
| 938/1507 | US=8 / Dermatologia Fitzpatrick JE. Mucocutaneous complications of antineoplastic therapy. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editores. Fitzpatrick's dermatology in general medicine. 6th ed. New York: McGraw-Hill, 2008. p. 1337-47. ISBN 978-0-07138076-0. TERAPIA ANTINEOPLASICA; COMPLICACOES MUCOCUTANEAS; FARMACOLOGIA |
| 939/1507 | US=80 / Biol/Mol Alaoui-Jamali MA, Pinto D. Proteomic profiling of tyrosine kinases as pharmacological endpoints for targeted cancer therapy. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 59-77. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. TIROSINA-QUINASES PROTEICAS; CANCER; TERAPIA-ALVO; PROTEOMICA |
| 940/1507 | US=84 / Biol/Mol Jakowlew SB. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: component hardware for transformig growth factor-B signal transduction: TGF-B ligands, TGF-B receptors, and smads. In: ___. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 3-21. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3. TGF-B LIGANTES; TGF-B RECEPTORES; SMAD; TRANSDUCAO DE SINAL; PROLIFERACAO |